OmniAb, Inc. (NASDAQ:OABI - Free Report) - Equities researchers at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of OmniAb in a research report issued to clients and investors on Wednesday, March 19th. HC Wainwright analyst J. Pantginis anticipates that the company will post earnings of ($0.15) per share for the quarter. HC Wainwright has a "Buy" rating and a $11.00 price objective on the stock. The consensus estimate for OmniAb's current full-year earnings is ($0.61) per share. HC Wainwright also issued estimates for OmniAb's Q2 2025 earnings at ($0.14) EPS, Q3 2025 earnings at ($0.13) EPS, FY2025 earnings at ($0.57) EPS, FY2026 earnings at ($0.36) EPS, FY2027 earnings at ($0.37) EPS and FY2028 earnings at ($0.27) EPS.
OmniAb (NASDAQ:OABI - Get Free Report) last released its quarterly earnings results on Tuesday, March 18th. The company reported ($0.12) EPS for the quarter, beating analysts' consensus estimates of ($0.13) by $0.01. The business had revenue of $10.80 million during the quarter, compared to analyst estimates of $10.13 million. OmniAb had a negative return on equity of 20.97% and a negative net margin of 308.78%. During the same period in the prior year, the firm posted ($0.14) EPS.
OABI has been the subject of several other research reports. Royal Bank of Canada decreased their price objective on shares of OmniAb from $7.00 to $4.00 and set an "outperform" rating for the company in a research note on Thursday. Benchmark decreased their price target on OmniAb from $8.00 to $6.00 and set a "buy" rating for the company in a research report on Thursday, March 20th.
Check Out Our Latest Research Report on OABI
OmniAb Price Performance
Shares of OABI stock traded up $0.04 on Monday, hitting $2.47. The stock had a trading volume of 636,814 shares, compared to its average volume of 537,754. OmniAb has a 12-month low of $2.23 and a 12-month high of $5.54. The stock has a market cap of $348.80 million, a price-to-earnings ratio of -3.98 and a beta of -0.14. The business has a 50 day moving average of $3.29 and a 200 day moving average of $3.73.
Insider Activity at OmniAb
In related news, CEO Matthew W. Foehr sold 41,811 shares of the business's stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $3.24, for a total value of $135,467.64. Following the sale, the chief executive officer now directly owns 3,749,639 shares in the company, valued at approximately $12,148,830.36. The trade was a 1.10 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director John L. Higgins acquired 125,750 shares of the company's stock in a transaction on Thursday, March 20th. The shares were acquired at an average cost of $2.35 per share, for a total transaction of $295,512.50. Following the completion of the acquisition, the director now owns 2,762,887 shares of the company's stock, valued at approximately $6,492,784.45. The trade was a 4.77 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders sold 112,260 shares of company stock worth $376,601. 8.60% of the stock is owned by company insiders.
Institutional Trading of OmniAb
Several hedge funds and other institutional investors have recently modified their holdings of OABI. Murchinson Ltd. purchased a new position in OmniAb in the 3rd quarter valued at approximately $4,230,000. JPMorgan Chase & Co. boosted its holdings in shares of OmniAb by 582.1% in the fourth quarter. JPMorgan Chase & Co. now owns 1,001,797 shares of the company's stock worth $3,546,000 after acquiring an additional 854,929 shares during the period. Royce & Associates LP grew its position in shares of OmniAb by 438.6% in the fourth quarter. Royce & Associates LP now owns 707,080 shares of the company's stock valued at $2,503,000 after purchasing an additional 575,796 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in shares of OmniAb by 4.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 3,025,674 shares of the company's stock valued at $10,711,000 after purchasing an additional 142,513 shares during the period. Finally, Northeast Financial Consultants Inc purchased a new stake in OmniAb during the 4th quarter worth about $393,000. Institutional investors own 72.08% of the company's stock.
About OmniAb
(
Get Free Report)
OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.
Recommended Stories
Before you consider OmniAb, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OmniAb wasn't on the list.
While OmniAb currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
